Chinese drugmaker Ganzhou Hemay Pharmaceutical has opened the books for its Hong Kong initial public offering, targeting up to HK$1.04 billion (about US$133 million) to bankroll its next wave of clinical development. The company is offering 55.2 million H shares at a maximum price of HK$18.90 each, according to an exchange filing cited by MT Newswires.
The deal is structured with an initial allocation of 5.5 million shares reserved for Hong Kong retail investors, while the remaining 49.7 million shares are aimed at international institutional buyers. That split can be adjusted depending on demand, a common feature in Hong Kong listings that allows underwriters to shift shares between tranches to meet investor appetite.
What is Ganzhou Hemay?
Ganzhou Hemay is a pharmaceutical company focused on developing treatments for inflammatory and autoimmune diseases. Its lead candidate, Mufemilast, is an oral small-molecule drug being studied for conditions such as psoriasis and psoriatic arthritis. The company plans to use the bulk of the IPO proceeds to advance Mufemilast through clinical trials and to support other pipeline programs.
The IPO comes amid a busy period for Hong Kong listings, particularly from Chinese biotech and tech firms seeking to tap international capital markets. HOSIN Electronics recently launched a HK$1.22 billion Hong Kong IPO, and Suzhou Denglin raised up to HK$1.76 billion for its GPU push. These deals reflect a broader trend of Chinese companies using Hong Kong as a gateway to global investors, especially when domestic listing channels are more restrictive.
Why this matters for investors
For everyday investors, an IPO like this offers a chance to own a piece of a clinical-stage drugmaker, but it comes with significant risks. Drug development is a long, expensive process with high failure rates. Even if Mufemilast shows promise in early trials, regulatory hurdles and competition from larger pharmaceutical companies can derail progress.
The pricing of the IPO—up to HK$18.90 per share—will be determined by investor demand during the bookbuilding period. If demand is strong, the final price may be set at the top of the range; if weak, it could be lowered. Retail investors in Hong Kong often participate in IPOs hoping for a first-day pop, but that is far from guaranteed, especially for smaller biotech listings.
Investors should also note that only a small portion of shares (about 10% of the offering) is initially set aside for Hong Kong retail. This is typical for larger deals, but it means retail investors may face a tight allocation if the deal is oversubscribed.
What to watch next
The success of Ganzhou Hemay's IPO will depend on several factors: the final pricing, the level of institutional interest, and the broader sentiment toward biotech stocks in Hong Kong. Recent listings in the sector have had mixed performances, with some trading above their offer prices and others falling below.
Investors should also keep an eye on the company's clinical milestones. Any positive or negative data from Mufemilast trials could move the stock significantly after listing. For now, the IPO is a bet on the company's pipeline and its ability to execute in a competitive market.
As with any IPO, it's wise to read the prospectus carefully and understand the risks before committing capital. The drugmaker's ability to deliver on its development plans will ultimately determine whether the shares are worth the price.
